The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer.
 
Yuki Yoshikawa
No Relationships to Disclose
 
Xin Victoria Wang
No Relationships to Disclose
 
Yu-Hui Chen
Employment - Constellation Pharmaceuticals (I); Flagship VL59 (I)
Stock and Other Ownership Interests - Constellation Pharmaceuticals (I)
 
Ying Zhang Mazzu
No Relationships to Disclose
 
Goutam Chakraborty
No Relationships to Disclose
 
Lina E. Jehane
No Relationships to Disclose
 
Sai Harisha Rajanala
No Relationships to Disclose
 
Rahim Hirani
No Relationships to Disclose
 
Subhiksha Nandakumar
No Relationships to Disclose
 
Konrad H. Stopsack
No Relationships to Disclose
 
Gwo-Shu Mary Lee
No Relationships to Disclose
 
Elai Davicioni
No Relationships to Disclose
 
Glenn Liu
Employment - AIQ Solutions
Leadership - AIQ Solutions
Stock and Other Ownership Interests - AIQ Solutions
Consulting or Advisory Role - Exelixis; Janssen; Novartis; Tricon Pharmaceuticals
Research Funding - Johnson & Johnson (Inst); Madison Vaccines, Inc.; Novartis (Inst); Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - I have patent pending titled "System and method for evaluation of disease burden" which provides a novel method to identify and quantitate treatment response. (Inst)
 
Robert S. DiPaola
No Relationships to Disclose
 
Michael Anthony Carducci
Consulting or Advisory Role - Abbvie; Astellas Pharma; Foundation Medicine; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); pfizer (Inst)
 
Philip W. Kantoff
Leadership - Context Therapeutics
Stock and Other Ownership Interests - Context Therapeutics; Druggablity Technologies; Placon; Seer; Tarveda Therapeutics
Consulting or Advisory Role - Bavarian Nordic; Context Therapeutics; Druggablity Technologies; GE Healthcare; Genentech/Roche; Janssen; Merck; New England Research Institutes; OncoCellMDX; Progenity; Sanofi; Seer; Tarveda Therapeutics; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties
Travel, Accommodations, Expenses - Druggablity Technologies
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination